Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa Clínica

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)	Advanced Non-small Cell Lung Cancer, HER2 Mutation	Recruiting	Phase 3	2026-09-23	NCT06452277
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)	Advanced Non-small Cell Lung Cancer; EGFR Mutation; HER2 Mutation	Recruiting	Phase 1 / Phase 2	2026-08-12	NCT05099172
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies	Biochemically Recurrent Prostate Cancer	Active, not recruiting	Phase 3	2026-07-07	NCT05794906
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer	cancer, neoplasm	Active, not recruiting	Phase 3	2026-07-07	NCT04464226

Clinical trials